Virginie Ferre

Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial.

Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial.

Journal: Open forum infectious diseases

Published: September 18, 2023

Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.

Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.

Journal: Antimicrobial agents and chemotherapy

Published: June 28, 2021

Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.

Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.

Journal: The Journal of antimicrobial chemotherapy

Published: February 25, 2021

Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort.

Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: February 04, 2021

Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.

Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.

Journal: Trials

Published: November 18, 2020

Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.

Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.

Journal: International journal of antimicrobial agents

Published: February 10, 2020

Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).

Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).

Journal: The Journal of antimicrobial chemotherapy

Published: January 08, 2020

Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

Journal: The Journal of antimicrobial chemotherapy

Published: May 27, 2019

Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.

Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.

Journal: The Journal of antimicrobial chemotherapy

Published: October 19, 2018

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.

Journal: The Journal of antimicrobial chemotherapy

Published: September 06, 2018

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.

Journal: The Journal of antimicrobial chemotherapy

Published: February 08, 2017

An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains.

An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains.

Journal: PloS one

Published: January 10, 2017

Showing 1-12 of 21

Last Updated: 09/26/2026